Author:
Joly F.,Ahmed-Lecheheb D.,Kalbacher E.,Heutte N.,Clarisse B.,Grellard J.M.,Gernier F.,Berton-Rigaud D.,Tredan O.,Fabbro M.,Savoye A.M.,Kurtz J.E.,Alexandre J.,Follana P.,Delecroix V.,Dohollou N.,Roemer-Becuwe C.,De Rauglaudre G.,Lortholary A.,Prulhiere K.,Lesoin A.,Zannetti A.,N’Guyen S.,Trager-Maury S.,Chauvenet L.,Abadie Lacourtoisie S.,Gompel A.,Lhommé C.,Floquet A.,Pautier P.
Reference28 articles.
1. Ovarian cancer;Jayson;Lancet,2014
2. Survie des personnes atteintes de cancer en France métropolitaine, 1989-2013. Partie1-Tumeurs solides, 1989-2013. Partie1-Tumeurs solides;Cowppli-Bony;Saint-Maurice: Institut de veille sanitaire,2016
3. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer;Helm;J Surg Oncol,2008
4. Monitoring physical and psychosocial symptom trajectories in ovarian cancer;Meraner;BMC Cancer,2012
5. Gynecologic Cancer Disease Site Group. Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline;Francis;Curr Oncol,2017